Literature DB >> 12453601

Oxidative stress and disturbed glutamate transport in spinal muscular atrophy.

Masaharu Hayashi1, Satoshi Araki, Nobutaka Arai, Satoko Kumada, Masahiro Itoh, Kimiko Tamagawa, Masaya Oda, Yoshio Morimatsu.   

Abstract

Spinal muscular atrophy (SMA) is a hereditary motor neuron disease, and three clinical subtypes of autosomal recessive SMA, including Werdnig Hoffmann disease (type 1), have been shown to be induced by deletion within the same genes. In order to clarify the pathogenesis of motor neuron degeneration in SMA, we immunohistochemically examine the expressions of oxidative stress-related materials (oxidative products) and glutamate transporters, which can prevent glutamate neurotoxicity, in five autopsy cases of SMA type 1. Age-matched controls did not show any deposition of oxidative products in the brain. In contrast, the abnormal deposition of 4-hydroxy-2-nonenal-modified protein, a product of membrane lipid oxidation, was observed in the spinal motor neurons in three cases, although the motor neurons did not show an increase of nitrotyrosine, which was observed in adult-onset amyotrophic lateral sclerosis. In addition, the nuclei of neurons and glial cells in the precentral gyrus, thalamus or cerebellar cortex were immunoreactive for 8-hydroxy-2'-deoxyguanosine in two cases, which was one of the most commonly used markers for oxidative DNA damage. Regarding glial glutamate transporters, three of five cases of SMA type 1 showed a reduction in immunoreactivity for excitatory amino acid transporter-1 (GLAST) in the ventrolateral nucleus of the thalamus, in which there was neither neuronal loss nor gliosis in routine histochemistry. One case, having mechanical ventilation, demonstrated a reduced expression of another glial glutamate transporter (GLT-1) throughout the central nervous system. These data suggest that oxidative stress and disturbed glutamate transport can partly be involved in the motor neuron devastation and/or latent thalamic degeneration in SMA type 1. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453601     DOI: 10.1016/s0387-7604(02)00103-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  16 in total

1.  Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.

Authors:  Monir Shababi; Javad Habibi; Lixin Ma; Jacqueline J Glascock; James R Sowers; Christian L Lorson
Journal:  J Mol Cell Cardiol       Date:  2012-01-17       Impact factor: 5.000

Review 2.  Inflammation in ALS and SMA: sorting out the good from the evil.

Authors:  Dimitra Papadimitriou; Virginia Le Verche; Arnaud Jacquier; Burcin Ikiz; Serge Przedborski; Diane B Re
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

3.  Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy.

Authors:  Po C Chen; Irina N Gaisina; Bassem F El-Khodor; Sylvie Ramboz; Nina R Makhortova; Lee L Rubin; Alan P Kozikowski
Journal:  ACS Chem Neurosci       Date:  2012-01-18       Impact factor: 4.418

Review 4.  Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Authors:  Osama A Abulseoud; Fawaz Alasmari; Abdelaziz M Hussein; Youssef Sari
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

5.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 6.  Revisiting the role of mitochondria in spinal muscular atrophy.

Authors:  Rachel James; Helena Chaytow; Leire M Ledahawsky; Thomas H Gillingwater
Journal:  Cell Mol Life Sci       Date:  2021-04-05       Impact factor: 9.261

7.  Altered gene expression, mitochondrial damage and oxidative stress: converging routes in motor neuron degeneration.

Authors:  Luisa Rossi; Cristiana Valle; Maria Teresa Carrì
Journal:  Int J Cell Biol       Date:  2012-05-17

8.  The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.

Authors:  Hong Liu; Armin Yazdani; Lyndsay M Murray; Ariane Beauvais; Rashmi Kothary
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 9.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

Review 10.  ROCK inhibition as a therapy for spinal muscular atrophy: understanding the repercussions on multiple cellular targets.

Authors:  Emmanuelle Coque; Cédric Raoul; Mélissa Bowerman
Journal:  Front Neurosci       Date:  2014-08-28       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.